Valuation: Indivior

Market Cap 4.91B 4.31B 3.97B 3.7B 6.97B 467B 7.11B 47.7B 18.48B 229B 18.43B 18.03B 797B P/E 2026 *
12.7x
P/E 2027 * 11.1x
Enterprise Value 4.96B 4.36B 4.01B 3.74B 7.05B 472B 7.19B 48.23B 18.69B 232B 18.63B 18.23B 806B EV / Sales 2026 *
3.94x
EV / Sales 2027 * 3.44x
Free-Float
94.38%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 4.91B
-0.64%+6.67%+53.59%+154.11% 1,063B
+0.00%+5.39%+62.89%+53.44% 611B
-0.23%+6.88%+32.14%+86.34% 444B
+1.76%-0.96%+26.12%+20.22% 324B
+1.81%+0.14%+35.53%+35.74% 285B
+0.91%+0.06%+28.09%+42.40% 283B
-0.66%+2.17%-26.95%-40.42% 219B
-0.22%+2.82%+24.37%+62.75% 195B
-0.29%+0.65%+12.75%+63.45% 156B
Average +0.34%+2.83%+27.62%+53.12% 397.85B
Weighted average by Cap. +0.33%+4.16%+38.28%+77.31%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.02B 947M 1.79B 120B 1.82B 12.23B 4.74B 58.7B 4.72B 4.62B 204B 1.31B 1.15B 1.06B 985M 1.86B 124B 1.9B 12.71B 4.93B 61.03B 4.91B 4.8B 212B
Net income 414M 364M 335M 312M 589M 39.4B 601M 4.03B 1.56B 19.34B 1.56B 1.52B 67.32B 473M 415M 382M 356M 672M 44.96B 685M 4.6B 1.78B 22.07B 1.78B 1.74B 76.8B
Net Debt 54.5M 47.85M 44.04M 41.04M 77.4M 5.18B 78.98M 530M 205M 2.54B 205M 200M 8.85B -403M -354M -326M -304M -573M -38.35B -585M -3.92B -1.52B -18.83B -1.51B -1.48B -65.52B
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-